NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)

CUSIP: N62509117

Q2 2026 13F Holders as of 30 Jun 2026

Share change
+12,845
SEC-reported price per share
$21.37
Indexed holders
9
Value change
+$274,397
Number of buys
2

Security key

N62509117

Report period

Q2 2026

Indexed institutions

9

Top holders

8

Ownership snapshot

Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Capital World Investors
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
4/15
Latest evidence
29 May 2026
13D/G 13F 3/4/5 Lead comparable stake: 10% 11 rows are not safely comparable across share classes. 13D/G row: Capital World Investors Showing 1-6 of 15 holder rows.

Quick read

Capital World Investors leads the comparable SEC ownership view at 10%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Capital World Investors's linked filing trail.
Comparable ownership Top 4
Capital World Investors 10%
Forbion Capital Fund IV Cooperati... 8.3%
VIKING GLOBAL INVESTORS LP 3.7%
BCLS II Investco, LP 1.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Capital World Investors
13D/G 13F
Company
10%
Reported 13D/G · 29 May 2026
$460,111,232
12,188,377 shares
+$89,303,892 29 May 2026
Forbion Capital Fund IV Cooperatief U.A.
13D/G
ForGrowth NAP B.V.
8.3%
Reported 13D/G · 26 Sep 2025
$223,140,090
9,316,914 shares
-$30,222,313 26 Sep 2025
VIKING GLOBAL INVESTORS LP
13D/G 13F
Company
3.7%
Reported 13D/G · 31 Dec 2025
$144,476,598
4,203,567 shares
-$95,375,616 31 Dec 2025
BCLS II Investco, LP
13D/G
BCLS Fund III Investments, LP
1.8%
Reported 13D/G · 12 May 2026
$74,671,230
2,059,896 shares
-$120,221,675 12 May 2026
ForGrowth NAP B.V.
3/4/5
10%+ Owner
—
denominator unverified
$272,125,599
10,656,172 shares
— 30 Dec 2024
Bain Capital Life Sciences Investors, LLC
3/4/5 13F
10%+ Owner · Company
—
mixed-class rows
$239,004,182
12,106,566 shares
mixed-class rows
— 13 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
9
Shares
1,309,194
Indexed holders
9
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 indexed holders
9
Q2 2026 indexed holders
9
Indexed holder difference
0
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .